Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulants.

J Hirsh1

  • 1Hamilton Civic Hospitals Research Centre and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada. jhirsh@thrombosis.hhscr.org

American Heart Journal
|August 2, 2001
PubMed
Summary
This summary is machine-generated.

New anticoagulants targeting the coagulation pathway are emerging, offering alternatives to traditional heparin and coumarins. Future oral anticoagulants must demonstrate superior safety and efficacy with reduced monitoring needs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.

Annals of internal medicine·1997
Same author

Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.

Circulation·1997
Same author

Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.

Circulation·1996
Same author

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.

Haemostasis·1996
Same author

Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo.

Blood·1996
Same author

The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.

Archives of internal medicine·1996
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Heparin and coumarins have been mainstays in anticoagulation for over 50 years.
  • Low-molecular-weight heparins (LMWHs) have been clinically utilized for over a decade.

Purpose of the Study:

  • To review the development and clinical evaluation of novel anticoagulants.
  • To discuss the mechanisms of action and potential applications of new anticoagulant agents.

Main Methods:

  • Review of recently developed anticoagulants targeting various coagulation steps.
  • Analysis of agents in phase II, III, and approved clinical use, including direct thrombin inhibitors.

Main Results:

  • Several novel anticoagulants targeting different points in the coagulation cascade have been developed.

Related Experiment Videos

  • Three direct thrombin inhibitors are approved, with others in advanced clinical trials.

    • Conclusions:

    • New oral anticoagulants must match or exceed the efficacy and safety of existing treatments.
    • Reduced monitoring requirements will be crucial for the clinical success of emerging oral anticoagulants.